Clinical Trials Logo

Filter by:
NCT ID: NCT05201794 Not yet recruiting - Dengue Clinical Trials

A Study of JNJ-64281802 for the Prevention of Dengue Infection

Start date: July 29, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to last day of dosing among participants who have no evidence of current DENV infection at baseline.

NCT ID: NCT05158387 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of MEDI3506 in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

Start date: February 7, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this Phase III study is to evaluate the efficacy and safety of MEDI3506 Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not indicated or contraindicated) in stable doses throughout at least 3 months prior to enrolment.

NCT ID: NCT05151055 Recruiting - Hormonal Acne Clinical Trials

Lactoferrin + Vitamin E + Zinc for Hormonal Acne

Start date: March 2, 2020
Phase: Phase 2
Study type: Interventional

We previously showed that twice daily intake of a combination of 100 mg lactoferrin, 11 IU vitamin E, and 5 mg zinc significantly reduced both inflammatory and non-inflammatory acne lesions compared to placebo control. In that study, females showed an overall better response compared to males in terms of total lesions. We speculated that the gender effect may be due to mitigation of the pre- menstrual flare-ups women have that lead to recurring acne, making them have a better response. The objectives of this study are: 1.) to characterize the efficacy and safety of 100 mg lactoferrin + 11 IU vitamin E + 5 mg zinc in the adult female population who suffer from hormonal acne, 2.) to determine whether the anti-acne effect is maintained after treatment stops.

NCT ID: NCT05113251 Recruiting - Breast Cancer Clinical Trials

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Start date: October 25, 2021
Phase: Phase 3
Study type: Interventional

This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.

NCT ID: NCT05099978 Recruiting - Ovarian Cancer Clinical Trials

Asian Multicenter Prospective Study of ctDNA Sequencing

Start date: November 1, 2021
Study type: Observational

This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types, analytical methods, participating countries, and participating institutions.

NCT ID: NCT05098899 Not yet recruiting - Clinical trials for Overweight and Obesity

Interventions Using Genomics-based Strategies (InGeSt) Towards Enhanced Nutrition Recommendations

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

The study aims to determine if genotype-based nutrition and lifestyle advice is effective for the management of overweight and obesity among Filipino adults compared to the usual standard of care.

NCT ID: NCT05096845 Recruiting - COVID-19 Pandemic Clinical Trials

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

Start date: August 25, 2021
Phase: Phase 3
Study type: Interventional

A Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older

NCT ID: NCT05096312 Completed - Acne Vulgaris Clinical Trials

Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients

Start date: December 21, 2018
Phase: Phase 4
Study type: Interventional

Acne Vulgaris is one of the most common dermatologic diagnoses requiring long-term maintenance therapy. Promising results of oral zinc gluconate in improving acne vulgaris has been described. A randomized, double blind, placebo-controlled clinical trial was utilized for this study with the objective to assess the efficacy of oral zinc gluconate in the improvement of disease activity in acne vulgaris patients as measured by the inflammatory score and Global Acne Grading System (GAGS) score.

NCT ID: NCT05079763 Recruiting - Clinical trials for Acute Radiation Dermatitis

Bacterial Cellulose-monolaurin Hydrogel for Acute Radiation Dermatitis

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

Acute radiation dermatitis (ARD) is almost universally experienced by patients with cancer during or after radiation therapy. This condition potebtxallt leads to detrimental clinical outcomes as it adversely affects adherence to prescribed subsequent management and further worsens quality of life. Nevertheless, there remains no consensus on the appropriate intervention for ARD. This pilot two parallel-group randomized trial aims to clinically assess the potential of bacterial cellulose-monolaurin hydrogel, compared to placebo cream, to prevent high-grade ARD among Filipinos with breast cancer up to four weeks after last radiotherapy session.

NCT ID: NCT05033639 Recruiting - Clinical trials for Necrotizing Enterocolitis

Efficacy Of Oral Melatonin To Prevent Necrotizing Enterocolitis

Start date: March 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Prematurity is still one of the primary causes of death in children under 5. 1-2. According to the WHO, 60% of all preterm births occur in Asia, with the Philippines accounting for around 348,900 every year. 3. Necrotizing enterocolitis is one of the fatal complications (NEC) 3, 4. Preterm newborns weighing 1500 grams or less are considered high risk. 5-6. Melatonin is one chemical that may help prevent NEC. Melatonin is an endogenous indolamine derived from serotonin. It is a ubiquitous molecule that is crucial to the body's physiologic function. Melatonin, also known as N-acetyl-5-methoxytryptamine, is an immunomodulator, antioxidant, anti-inflammatory, and free radical scavenger7-10. It is a naturally occurring chemical that is simply replenished. With this in mind, the researcher wants to see if providing high dose melatonin to premature babies can prevent NEC.